TAVR has shown improvement in a patient's health as early as 30 days after their procedure. Patients reported improvements in quality of life, including:
It is important to talk with your doctor about the exact procedure you will have, the product you will receive, and the literature on clinical studies using that product.
*See the Edwards SAPIEN 3 valve patient brochure for more detailed information on these and other risks.
The most common way to perform TAVR is through the transfemoral approach. An incision will be made in your leg, where your doctor will insert a short, hollow tube called a sheath.
The Edwards SAPIEN 3 transcatheter heart valve will be placed on the delivery system and compressed on a balloon. The delivery system carrying the valve will be placed through the sheath and delivered to your aortic valve. The balloon of the delivery system will be inflated, expanding the new valve within your diseased valve.
The valve will push the leaflets of your diseased valve aside, securing itself into place. The new valve should begin working immediately.
To find out if TAVR is right for you, please talk with your doctor and locate a TAVR Center near you.
*First clinical use
*CE mark approval in Europe 2007